Cargando…
Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
INTRODUCTION: Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board...
Autores principales: | Sun, Li, Yang, Meng, Zhang, Xuan, Li, Hua, Wu, Lingying, Zhang, Yuzi, Cai, Shangli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253621/ https://www.ncbi.nlm.nih.gov/pubmed/32443311 http://dx.doi.org/10.1097/MD.0000000000020053 |
Ejemplares similares
-
Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016) -
Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Zhang, Yawen, et al.
Publicado: (2020) -
GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report
por: Zhuang, Yuan, et al.
Publicado: (2021) -
Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study
por: Guo, Qiufen, et al.
Publicado: (2020) -
Bevacizumab combined with chemotherapy for ovarian cancer: A protocol for systematic review and meta-analysis
por: Liao, Ting, et al.
Publicado: (2021)